Skip to main content

Advertisement

Table 1 Patient demographics and clinical characteristics of de novo prostate cancer patients with bone metastases (N = 16,643)

From: Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients

CharacteristicsLevelNumber (%)
Age at diagnosisMean ± SD71.41 ± 11.318
Median (range)71 (34–105)
≤ 708079 (48.5%)
> 708564 (51.5%)
RaceWhite12,367 (74.3%)
Black303 (18.2%)
Asian or Pacific Islander989 (5.9%)
Others/unknown257 (1.5%)
Marital statusMarried8987 (54.0%)
Unmarried6542 (39.3%)
Unknown1114 (6.7%)
Tumor gradeWell differentiated96 (0.6%)
Moderately differentiated861 (5.2%)
Poorly differentiated9097 (54.6%)
Undifferentiated87 (0.5%)
Unknown6502 (39.1%)
PSA≤ 10 ng/ml1271 (7.6%)
10–20 ng/ml1240 (7.4%)
20–50 ng/ml2037 (12.2%)
> 50 ng/ml10,336 (62.1%)
Unknown1759 (10.6%)
Gleason≤ 6219 (1.3%)
3 + 4536 (3.2%)
4 + 3885 (5.3%)
8–108052 (48.4%)
Unknown6951 (41.8%)
Metastatic sitesBone-only14,872 (89.4%)
Bone and lung976 (5.9%)
Bone and liver414 (2.5%)
Bone and brain126 (0.8%)
Bone and ≥ 2 other sites255 (1.3%)
SurgeryYes1593 (9.6%)
No/unknown15,085 (90.4%)
RadiotherapyYes3765 (22.6%)
No/unknown12,878 (77.4%)
ChemotherapyYes2216 (13.3%)
No/unknown14,427 (86.7%)
  1. PSA prostate specific antigen